Research Article

Cardiovascular Protective Effects of Salvianic Acid A on db/db Mice with Elevated Homocysteine Level

Lei Gao,¹ Parco M. Siu,² Shun-wan Chan,³ and Christopher W. K. Lai¹

¹Department of Health Technology and Informatics, Hong Kong Polytechnic University, Hung Hom, Hong Kong
²School of Public Health, The University of Hong Kong, Pokfulam, Hong Kong
³Faculty of Science and Technology, Technological and Higher Education Institute of Hong Kong, Tsing Yi, Hong Kong

Correspondence should be addressed to Christopher W. K. Lai; chris.lai@polyu.edu.hk

Received 29 April 2017; Revised 15 July 2017; Accepted 6 August 2017; Published 17 September 2017

Academic Editor: Patricia Morales

Copyright © 2017 Lei Gao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The onsets of left ventricular hypertrophy (LVH) and endothelial dysfunction (ED) in diabetics, especially in those with elevated homocysteine (Hcy), precede the development of cardiovascular (CV) events. Salvianic acid A (SAA) is a renowned Traditional Chinese Medicine (TCM) that has been applied in the treatment of cardiovascular disease for many decades. In this study, we aimed (1) to investigate the CV protective effects of SAA on ameliorating LVH and ED in db/db mice with elevated blood Hcy level and (2) to decipher whether the observed CV protective effects of SAA are associated with Hcy metabolism by modulating the methylation potential and redox status in the liver of the db/db mice with elevated blood Hcy level. Our results found that the administration of SAA could significantly slow down the build-up of left ventricular mass and ameliorate ED. Immunological assay analysis on the mouse liver tissue also indicated that SAA treatment on db/db mice with elevated Hcy was associated with reduced methylation potential but improved redox status. In conclusion, we revealed that SAA has the potential to protect against the hyperglycemia- and hyperhomocysteinemia-induced oxidative stress on diabetic mice via modulation in Hcy metabolism.

1. Introduction

In 2013, 382 million people in the world were living with diabetes mellitus (DM), and the figure is expected to rise drastically to about 600 million by 2035 [1]. There is a growing evidence suggesting that DM is coupled with increased oxidative stress and altered redox state and leads to subsequent onsets of cardiomyopathy [2, 3] and endothelial dysfunction (ED) [4, 5]. Remarkably, diabetic patients are exposed to a higher risk to develop hyperhomocysteinemia (HHcy) when compared to nondiabetic subjects, particularly in those taking metformin antidiabetic medication [6, 7]. According to a previous cohort study in 122 type 2 DM patients, the prevalence of HHcy in type 2 diabetes was 31% [8]. Recent evidences have shown that both long-term and short-term metformin treatments could lead to elevation of Hcy in type 2 DM patients due to reduction of serum folate and Vitamin B12 [9–11]. Today, both hyperglycemia and HHcy status have been recognized as strong cardiovascular disease (CVD) risk factors or predictors [12, 13], and HHcy status was strongly associated with the development of diabetes and diabetic CV complications [11, 14, 15].

Diabetic cardiomyopathy is one of the common diabetic heart complications characterized by left ventricular hypertrophy (LVH), fibrotic changes in the myocardium, and thickening of intramural arterioles in the absence of hypertension and atherosclerosis [16]. Patients with diabetes are well known to have increased risk in the development of LVH owing to the clustering of several CV risk factors, including hypertension, hypercholesterolemia, HHcy, and endothelial dysfunction (ED). It has been reported that HHcy triggers oxidative stress in the heart and leads to cardiac hypertrophy and the subsequent cardiac diastolic
function disorder via diminished activity of peroxisome proliferator-activated receptor [17, 18]. Apart from the adverse effects on the heart, extensive clinical and review studies have reported that HHcy status could also impair endothelium-dependent vasodilation in diabetics [19–22]. Interestingly, several previous studies have shown that a short-term Hcy-lowering therapy could improve ED in hypertensive patients [23], and a lower methylation potential (S-adenosylmethionine (SAM) to S-adenosylhomocysteine (SAH) ratio) played a significant role in CVD [24]. These findings therefore suggest that Hcy metabolism might be involved and could serve as a potential treatment pathway to reduce CVD burden in diabetes.

Methylation potential (S-adenosylmethionine (SAM) to S-adenosylhomocysteine (SAH) ratio) and redox status (glutathione (GSH) to glutathione disulfide (GSSG) ratio) are closely linked to Hcy metabolism and are responsible for the clearance of elevated Hcy via the remethylation and transsulfuration pathways. Remethylation converts methionine via SAM and SAH into Hcy in a reversible cycle. Meanwhile, Hcy could also irreversibly transform to GSH via the transsulfuration pathway. As an important intracellular antioxidant, GSH plays a significant role in the redox balance and cell apoptosis [25–28]. GSH reduction was reported as a crucial cause of cardiac cell apoptotic death in diabetic rats, and supplement of GSH could prevent the diabetic rats from heart disease effectively by reversing cell apoptosis and mitochondrial oxidative stress [29]. Generally, SAH level is usually high in subjects with elevated Hcy level because the process of remethylation is a reversible process that catalyzed by SAM and is always at equilibrium due to the high activity of SAH [30]. Also, GSSG is the oxidized form of GSH, and the ratio between GSH and GSSG is fundamental for the maintenance of redox status balance [31, 32].

Danshen is a typical Traditional Chinese Medicine (TCM). It is the dried root of Salvia miltiorrhiza that has been used in the treatment of CVD for a long period of time [33]. The earliest use of it was first recorded in the books “Shen Nong’s Herbal Classic” (First century B. C. – First century A.D. Eastern Han dynasty). According to the TCM theory, Danshen can “remove blood stasis.” Salvianic acid A (SAA), or Danshensu with the chemical name of 3-(3,4-dihydroxyphenyl)-2-hydroxypropanoic acid (Figure 1), is one of the major active ingredients in the water-soluble components that extracted from Danshen. It has been proven to possess diverse pharmacological effects such as improving blood circulation, inhibiting platelet adhesion and aggregation, acting against oxidative stress by suppressing the production of reactive oxygen species (ROS), preventing the onset of myocardial ischemia, and ameliorating endothelial cell dysfunction [34–38]. Today, the effects of SAA on ameliorating the progression of LVH and ED are poorly studied, particularly in diabetes with elevated Hcy level. A previous similar study reported that SAA treatment could markedly attenuate HHcy in nondiabetic rats through enhanced production of GSH via activated transsulfuration pathway [39], but whether SAA could exert similar effects on attenuating elevated Hcy level and CVD burdens in a diabetic animal with HHcy is still not clearly understood. Therefore, in the present study, we proposed (1) to investigate the CV protective effects of SAA on ameliorating LVH and ED in db/db mice with elevated blood Hcy level and (2) to decipher whether the observed CV protective effects of SAA are associated with the modulation of methylation potential and redox status in the liver of the db/db mice with elevated blood Hcy level.

2. Materials and Methods

2.1. Animals and Intervention. Female diabetic homozygous db/db mice and nondiabetic heterozygous db/m mice of 10 wks old were housed in the Central Animal Facilities of the Hong Kong Polytechnic University, in a 12 h light/darkness cycle, at a temperature of 20–25°C and humidity of 50–60%. They were allowed regular laboratory chow and tap water ad libitum throughout the experimental period. All the db/db mice were then divided into four groups (n = 6–9): (G1) DM (control); (G2) DM (SAA); (G3) DM (methionine); and (G4) DM (methionine + SAA). Nondiabetic db/m mice (n = 10) were grouped as the non-DM group (G5). During the intervention period of 8 wks, all mice were treated according to the following schedule: G1 and G5 received no treatment; G2 received SAA (purity ≥ 98%, Nanjing Zelang Pharmaceutical Technology Co. Ltd., Nanjing, China) at dose of 60 mg·kg−1·day−1 by gastric intubation; G3 received methionine (purity ≥ 98%, Sigma-Aldrich, St. Louis, Missouri, USA) that was dissolved in tap water as 1% (v/v), and the water was refreshed every 3 days; and G4 received both SAA (60 mg·kg−1·day−1 by gastric intubation) and methionine in water (1% (v/v)). Experimental protocols were performed in accordance with the approved license granted under the Department of Health and approved by the Animal Subjects Ethics Sub-Committee (ASESC) of Hong Kong Polytechnic University.

Fasting blood glucose, echocardiographic, and biochemical parameters were assessed at baseline and at the end of the intervention period. After an overnight fasting for 10 hrs, blood samples were collected from the tail vein of mice at baseline and after intervention for the determination of fasting blood glucose level using a test strip and a glucose meter (Bayer Contour TS, Bayer Inc., Leverkusen, Germany). Then, at the end of an 8 wk intervention, all mice were euthanized. Whole blood was collected by heart puncture and centrifugated at 13,000 rpm in 4°C for 15 min. The serum was then moved to new tubes, snap frozen by liquid nitrogen, and stored under −80°C for later analysis. The liver
tissues of the mice were rapidly excised, weighted and washed with phosphate buffered saline, then maintained in centrifuge tubes and snap frozen in liquid nitrogen and stored under −80°C for later analysis. Finally, dissected thoracic aorta tissues were collected carefully and isolated from the surrounding connective tissues and fat and were then cut into aorta rings with a length of around 2 mm for later analysis using myography. This procedure was performed under a dissection microscope with the dissected aorta immersed in Krebs’ buffer.

2.2. Transthoracic Echocardiography Assessment. At baseline and the end of intervention, all mice were arranged to undergo transthoracic echocardiographic assessment using an ultrasound system (model: HD11 XE, Philips Medical Systems, Bothell, WA, USA) with a high-resolution broadband compact linear array transducer (model: L15-7i0, Philips Medical Systems, Bothell, WA, USA) according to the protocol of our previous work [40]. Mice were anesthetized with an intraperitoneal injection of ketamine (80 mg/kg)/xylazine (10 mg/kg) mixture and rested on a heating pad to maintain their body temperature during the whole scanning procedure. Then, the hair on their ventral thorax was carefully shaved. During echocardiography, the mice were positioned in prone decubitus position, and the cardiac structure in parasternal short-axis view at the papillary level was determined using B-mode. Then, the left ventricular (LV) interventricular septal thicknesses (IVS), LV internal dimensions (LVID), and posterior wall thicknesses (PW) at the diastole and systole were carefully measured using M-mode at the level of the papillary muscles (Figure 2). Finally, LV ejection fraction (EF), LV fractional shortening (FS), and LV mass were calculated using the following [41]:

\[
\text{EF\%} = 100 \times \frac{\text{LVID}^d - \text{LVID}s}{\text{LVID}^d}, \\
\text{FS\%} = 100 \times \frac{\text{LVID}d - \text{LVID}s}{\text{LVID}d}, \\
\text{LV mass} = 1.05 \times [(\text{IVS}d + \text{LVID}d + \text{PW}d)^3 - \text{LVID}d^3].
\]

2.3. Endothelial Function Assessment. Immediately after scarification, the mouse aortas were cut into pieces as aortic rings, and mounted in a Wire Myograph System (610M, Danish Myo Technology, Aarhus, Denmark) using two parallel L-shaped metal prongs that connected with a force transducer. The change in isometric tension of the dissected aortic ring was monitored and recorded by a real-time force acquisition programme, LabChart Pro software (AD Instruments, Sydney, Australia). During the whole procedure, the prepared aortic rings were bathed with 5 mL Krebs’ buffer at a temperature of 37°C and with a continuous supply of 95% O2 and 5% CO2 mixture. After 1 hr of equilibrium, the prepared aortic rings were challenged with 60 mM potassium chloride to confirm its bioactivity. Then, the aorta rings were washed again and challenged by phenylephrine (10−6 M) for precontraction until stabilized. Acetylcholine (Ach) at an accumulative concentration from 10−8 M to 10−6 M was then added to determine endothelium-dependent dilation, and the whole process was then repeated by adding sodium nitroprusside (SNP) at accumulative concentration from 10−10 M to 10−5 M to determine endothelium-independent dilation. Cumulative concentration-response curves (from 1/10nM to 100 mM) were constructed, and the vasorelaxation capacity in response to Ach or SNP was expressed as % at different contractions, where 100% relaxation was considered when the active tone had returned to the baseline level. Krebs’ buffer, potassium chloride, acetylcholine, phenylephrine, and sodium nitroprusside were all obtained from the Sigma Chemical Company (Poole, Dorset, U.K.).

2.4. Biochemical Measurement. Serum Hcy level was determined according to a previous study with minor modification [42]. In brief, 10 μL of serum sample was injected into a high-performance liquid chromatography system which consisted of a Waters 2695 Separation Module (Waters Corporation, Milford, MA, USA), a Waters 474 Detector (Waters Corporation, Milford, MA, USA), and an analytical column (Agilent Zorbax Eclipse XDB-C18, 5 μm, 4.6 × 150 mm, Agilent Technologies, Santa Clara, CA, USA) with a guard column (Waters Symmetry C18, 5 μm, 3.9 × 20 mm, Waters Corporation, Milford, MA, USA). Mobile phase A was set at 50 mM KH2PO4 (pH = 5.0), and mobile phase B was set at 50 mM KH2PO4-methanol 1 : 1 (v/v) (pH = 5.0). The flow rate in the column was set at 1.2 mL/min for 10 min. Finally, the concentration of Hcy was determined by measuring the
Table 1: Fasting blood glucose level and body weight at the beginning and end of the experiment.

|                      | DM (control)       | DM (SAA)           | DM (methionine)   | DM (methionine + SAA) | Non-DM       |
|----------------------|--------------------|--------------------|-------------------|------------------------|--------------|
| **Baseline**         |                    |                    |                   |                        |              |
| Fasting blood glucose (mmol/L) | 27.73 ± 2.08*     | 22.72 ± 1.50*     | 27.72 ± 2.14*     | 23.99 ± 1.71*          | 5.94 ± 0.50  |
| Body weight (g)      | 42.95 ± 2.33*     | 44.63 ± 1.22*     | 44.76 ± 1.43*     | 48.42 ± 1.39*          | 22.14 ± 0.58 |
| **After 8 wks**      |                    |                    |                   |                        |              |
| Fasting blood glucose (mmol/L) | 29.18 ± 1.67*     | 27.08 ± 1.23*     | 25.77 ± 0.75*     | 25.64 ± 1.65*          | 5.43 ± 0.45  |
| Body weight (g)      | 49.56 ± 4.83*     | 56.82 ± 2.68*     | 49.06 ± 3.16*     | 53.12 ± 2.78*          | 25.36 ± 0.53 |

*P < 0.001 when compared to the non-DM group.

**Results**

3.1. **Fasting Blood Glucose, Body Weight, and Serum Hcy Level.** All the db/db mice exhibited significantly higher fasting blood glucose level and were more obese than the db/mice both at the beginning and at the end of the intervention. However, the fasting blood glucose level in each group was similar before and after 8 wks of intervention period (Table 1). Elevated Hcy levels were successfully induced by using 1% w/v of methionine in water for 8 wks in the db/db mice of the DM (methionine) and DM (methionine + SAA) groups and were evidenced by a 6-fold of increment when compared to the other groups without taking methionine in water (Figure 3). Specifically, consumption of methionine in water significantly elevated the serum Hcy levels in both DM (methionine) group (45.39 ± 7.95 μM) and DM (methionine + SAA) group (26.89 ± 4.17 μM) when compared to the DM (control) group (6.70 ± 0.47 μM) that is taking normal tap water. Besides, the expected elevation of Hcy level after 8 wk of SAA cotreatment in the DM (methionine + SAA) group was significantly reduced when compared to the DM (methionine) group (Figure 3), implicating that DSS has a Hcy-lowering effect on this group.

Interestingly, the observed Hcy-lowering effect of SAA was not found in the DM (SAA) group, suggesting that SAA might selectively exert its Hcy-lowering effect on diabetic mice with elevated Hcy level only and have little or no effect on those db/db mice with normal Hcy level.

3.2. **Echocardiographic Assessment.** We found that the two diabetic groups without taking SAA treatment (DM (control) and DM (methionine)) exhibited increased PWd (58.5%, P < 0.01; 58.2%, P < 0.05), PWS (31.6%, P < 0.05; 32.5%, P < 0.05), LVSD (38.1%, P < 0.05; 25.4%, P < 0.001), and LV mass (49.0%, P < 0.001; 31.7%, P < 0.01) at the end of intervention period when compared to their baseline values (Table 2). On the contrary, the LV mass in the two SAA-treated diabetic groups (DM (SAA) and DM (methionine + SAA)) was significantly lower than that in the DM (control) group, suggesting a delay in the progression of LVH in the db/db mice treated with SAA for 8 wks (Figure 4). Nevertheless, the cardiac function as represented by EF and DS before and after 8 wks was similar in all groups, implicating that SAA might have limited impacts on improving cardiac function, or the intervention period of 8 wks was

**Fluorescence signal captured at an excitation wavelength of 385 nm and an emission wavelength of 515 nm.**

SAM and SAH levels in liver tissues were determined following the instruction of commercial ELISA kits (item numbers IK00202S and IK00302S, Arthus Biosystems, LLC, Richmond, CA, USA). The SAM/SAH ratio was calculated to denote methylation potential. Glutathione (GSH) and glutathione disulfide (GSSG) levels in the liver tissue were determined using GSH assay kit (item number 703002, Cayman Chemical, Ann Arbor, Michigan, USA). The GSH/GSSG ratio was calculated to denote redox status.

2.5. **Statistical Analysis.** All data were analyzed using IBM SPSS Statistics (version 21.0, IBM SPSS Inc., Chicago, IL, USA) and represented as mean ± SEM. Comparison among the multiple groups was conducted by one-way ANOVA followed by post hoc Bonferroni test, while the mean differences between baseline and post measurements were analyzed by paired t-test. A P value of less than 0.05 was considered significant. All figures were generated using GraphPad Prism software (version 5.01, GraphPad software Inc., San Diego, CA, USA).
| Echocardiography parameters | DM (control) | DM (SAA) | DM (methionine) | DM (methionine + SAA) | Non-DM |
|----------------------------|--------------|----------|----------------|-----------------------|--------|
| Baseline                  | Post         | Baseline | Post           | Baseline              | Post   |
| HR (bpm)                  | 265.78 ± 14.22 | 249.93 ± 14.23 | 257.65 ± 12.47 | 263.32 ± 5.81 | 263.77 ± 14.00 |
| LVIDd (mm)                | 3.79 ± 0.12  | 3.54 ± 0.20  | 3.96 ± 0.12  | 4.04 ± 0.11  | 3.80 ± 0.07  |
| LVIDs (mm)                | 2.08 ± 0.05  | 2.13 ± 0.16  | 2.34 ± 0.11  | 2.25 ± 0.11  | 2.03 ± 0.08  |
| PWd (mm)                  | 0.53 ± 0.10  | 0.84 ± 0.09**| 0.49 ± 0.01  | 0.53 ± 0.02  | 0.55 ± 0.04  |
| PWs (mm)                  | 0.79 ± 0.04  | 1.04 ± 0.08* | 0.80 ± 0.02  | 0.87 ± 0.03  | 0.83 ± 0.04  |
| IVSd (mm)                 | 0.63 ± 0.06  | 0.87 ± 0.07* | 0.62 ± 0.02  | 0.58 ± 0.03  | 0.67 ± 0.02  |
| IVSs (mm)                 | 1.08 ± 0.05  | 1.16 ± 0.09  | 1.06 ± 0.06  | 1.02 ± 0.05  | 1.02 ± 0.03  |
| LV mass (mg)              | 69.98 ± 2.54 | 104.29 ± 4.63*** | 71.54 ± 2.27 | 73.63 ± 2.86 | 75.66 ± 2.40 |
| LV EF (%)                 | 83.11 ± 1.29 | 78.02 ± 2.10 | 82.33 ± 1.42 | 84.25 ± 1.50 | 80.68 ± 3.26 |
| LV FS (%)                 | 45.11 ± 1.45 | 40.08 ± 1.86 | 40.77 ± 2.03 | 44.30 ± 1.57 | 46.67 ± 1.71 |

HR: heart rate; LVIDd: left ventricular internal dimensions (diastole); LVIDs: left ventricular internal dimensions (systole); PWd: posterior wall thicknesses (diastole); PWs: posterior wall thicknesses (systole); IVSd: interventricular septal thicknesses (diastole); IVSs: interventricular septal thicknesses (systole); EF: left ventricular ejection fraction; FS: left ventricular fractional shortening; LV mass: left ventricular mass. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001 when compared to its corresponding baseline values.
3.4. Endothelial Function Assessment. The results of vascular endothelial function assessments were summarized using concentration-dependent relaxation curves and expressed in Figures 5 and 6. At the concentration of $10^{-6}$ M–$10^{-7}$ M of Ach, significant reduction in the percentage of Ach-induced relaxation was observed in all the diabetic groups when compared to the non-DM group. From $10^{-6}$ M to $10^{-6}$ M, the reductions in endothelium-dependent relaxations in DM (control) and DM (SAA) were gradually attenuated or improved to an extent similar to the non-DM group. For the DM (SAA + methionine) group, the percentage of relaxation induced by Ach was not improved to the extent similar to the non-DM group until the Ach concentration reached $10^{-6}$ M. However, the reduction in the percentage of Ach-induced relaxation persists in the DM (methionine) group at all concentrations of Ach. Conversely, the percentage of relaxation induced by SNP in all diabetic groups was similar when compared to that in the non-DM group, except at the concentrations from $10^{-8}$ M to $10^{-7}$ M where significantly diminished relaxations were observed in the DM (methionine) group when compared to the non-DM group.

4. Discussion

Diabetes is a multifactorial disease that leads to various forms of CVD complications. In this study, we collected evidences that SAA, apart from being a potent antioxidant, could possibly serve as a Hcy-lowering drug in diabetes with HHcy and at the same time exert multiple beneficial effects on the cardiovascular system. The present study indicated that oral administration of SAA for 8 wks could delay the progression of LVH and ameliorates ED in db/db mice, in particular to those with elevated Hcy level. These observed beneficial cardiovascular effects by SAA in our studied diabetic mice model with elevated Hcy level might be due to an improved redox status by the antioxidant effect of SAA itself and by the increased production of GSH via activated transsulfuration pathway.

Besides, our results indicated that SAA treatment did not significantly affect the serum Hcy level in the diabetic mice with a normal level of Hcy, while clearly lowering down the serum Hcy level in the diabetic mice with elevated Hcy level. This observation might suggest that the beneficial effect of SAA in lowering Hcy level largely depends on the baseline initial value of serum Hcy level of the db/db mice. We found that a previous study also exhibited a similar bidirectional Hcy-lowering effect of SAA in the nondiabetic rats [39]. Interestingly, the Hcy level was found lowered in db/db mice when compared to db/m mice in our study, though it has not reached a significant difference, probably due to (1) a decreased level of methionine in the liver, (2) the sulfur-containing byproduct generated during the methionine metabolism, and (3) a diminished transmethylation activity in the methionine metabolism [43]. Remarkably, as a transgenic diabetic mouse model, db/db mice were reported previously as possessing a lower Hcy level when compared to db/+ mice [43].

5. The CV Protective Effects of SAA on Ameliorating LVH and ED in db/db Mice with Elevated Blood Hcy Level

As reported in the previous studies, SAA has been indicated to inhibit platelet adhesion and aggregation, act against oxidative stress by suppressing the production of ROS, protect...
when compared to the non-DM group; was similar to the non-DM group and significantly lower than that in the DM (control) group, suggesting that SAA treatment could prevent or slow down the progression of diabetic LVH (Figure 4).

ED is the initial step in the pathogenesis of atherosclerotic CVD. In the endothelium-dependent vasorelaxation test induced by Ach, the diabetic groups with SAA treatment were found capable to ameliorate the detrimental effect of both hyperglycemia and Hcy in a dose-dependent manner (Figure 5). Besides, the additive detrimental effect of both hyperglycemia and HHcy together with the endothelial dysfunction via Akt and ERK1/2 phosphorylation [35, 44]. In diabetes, excessive ROS generation could be triggered by hyperglycemia and autoxidation [45]. Elevated ROS was found associated with increased cell death and apoptosis in the heart of the db/db mice [46], which led to pathological cardiac remodeling and fibrosis [47] and subsequent abnormal cardiac morphological and functional change [48]. Consistent with a previous study [49], the presence of LVH was found in the DM (control) group, as evidenced by the increased LV mass and wall thickness after 8 wks. With the 8 wks SAA treatment in the DM (SAA) and DM (methionine + SAA) groups, we found the LV mass in these 2 groups was similar to the non-DM group and significantly lower than that in the DM (control) group, suggesting that SAA treatment could prevent or slow down the progression of diabetic LVH (Figure 4).

Figure 5: Endothelium-dependent vasorelaxation induced by acetylcholine (Ach). $P < 0.05$, $**P < 0.01$, and $***P < 0.001$ when compared to the non-DM group; $\Delta P < 0.05$, $\beta P < 0.01$, and $\beta\beta P < 0.001$ when compared to the DM (control) group. $\Delta P < 0.05$ when compared to the DM (SAA) group.

Figure 6: Endothelium-independent vasorelaxation induced by sodium nitroprusside (SNP). $P < 0.05$ when compared to the non-DM group.

myocardium ischemia, and ameliorate endothelial cells dysfunction via Akt and ERK1/2 phosphorylation [35, 44]. In diabetes, excessive ROS generation could be triggered by hyperglycemia and autoxidation [45]. Elevated ROS was found associated with increased cell death and apoptosis in the heart of the db/db mice [46], which led to pathological cardiac remodeling and fibrosis [47] and subsequent abnormal cardiac morphological and functional change [48]. Consistent with a previous study [49], the presence of LVH was found in the DM (control) group, as evidenced by the increased LV mass and wall thickness after 8 wks. With the 8 wks SAA treatment in the DM (SAA) and DM (methionine + SAA) groups, we found the LV mass in these 2 groups was similar to the non-DM group and significantly lower than that in the DM (control) group, suggesting that SAA treatment could prevent or slow down the progression of diabetic LVH (Figure 4).

ED is the initial step in the pathogenesis of atherosclerotic CVD. In the endothelium-dependent vasorelaxation test induced by Ach, the diabetic groups with SAA treatment were found capable to ameliorate the detrimental effect by elevated blood glucose and Hcy in a dose-dependent manner (Figure 5). Besides, the additive detrimental effect of both hyperglycemia and HHcy together with the endothelial dysfunction in the DM (methionine) group was evidenced by a relatively lower percentage of Ach-induced vasorelaxation at a concentration of $10^{-7.5} \text{M}$ to $10^{-6} \text{M}$ when compared to the DM (control) group. On the contrary, the endothelium-independent vasorelaxation induced by SNP in all groups were similar at all concentrations of SNP (Figure 6),

### Table 3: The methylation status (SAM/SAH ratio) in the liver of the mice at the end of the experiment.

|                  | DM (control) | DM (SAA) | DM (methionine) | DM (methionine + SAA) | Non-DM |
|------------------|--------------|----------|-----------------|-----------------------|--------|
| SAM (μg/g)       | 0.101 ± 0.01 | 0.051 ± 0.003 | 0.133 ± 0.021*   | 0.089 ± 0.011          | 0.062 ± 0.007 |
| SAH (μg/g)       | 0.112 ± 0.027 | 0.100 ± 0.027** | 0.156 ± 0.010   | 0.212 ± 0.024          | 0.098 ± 0.025*** |
| SAM/SAH ratio    | 1.57 ± 0.75*** | 0.94 ± 0.37 | 0.86 ± 0.13     | 0.46 ± 0.08            | 0.93 ± 0.19 |

SAM: S-adenosylmethionine; SAH: S-adenosylhomocysteine. All values are expressed as concentration (μg/g) per 1 g of liver tissue. $*P = 0.01$ versus the non-DM and DM (SAA) groups. $**P < 0.05$ versus the DM (methionine + SAA) group. $***P < 0.01$ versus the DM (methionine + SAA) group.

### Table 4: GSH, GSSG, and oxidative stress (GSH/GSSG ratio) in the liver tissue at the end of the experiment.

|                  | DM (control) | DM (SAA) | DM (methionine) | DM (methionine + SAA) | Non-DM |
|------------------|--------------|----------|-----------------|-----------------------|--------|
| GSH (mg/g)       | 3.04 ± 0.13** | 3.53 ± 0.17** | 3.06 ± 0.17**   | 3.77 ± 0.10           | 4.28 ± 0.18 |
| GSSG (mg/g)      | 0.85 ± 0.17  | 0.62 ± 0.21*  | 0.57 ± 0.06*    | 0.78 ± 0.07           | 1.14 ± 0.12 |
| Oxidative stress (GSH/GSSG ratio) | 4.05 ± 0.47** | 9.13 ± 2.24 | 5.60 ± 0.47 | 5.20 ± 0.58 | 4.11 ± 0.45** |

GSH: glutathione; GSSG: oxidized glutathione. $*P < 0.001$ versus the non-DM group. $**P < 0.05$ versus the non-DM group. $*P < 0.05$ versus the DM (methionine + SAA) group. $*P < 0.05$ versus the DM (SAA) group. $**P < 0.01$ versus the non-DM group. $***P < 0.001$ versus the non-DM group.

### Figure 5: Endothelium-dependent vasorelaxation induced by acetylcholine (Ach).

Figure 6: Endothelium-independent vasorelaxation induced by sodium nitroprusside (SNP). $P < 0.05$ when compared to the non-DM group.
suggesting that the observed impaired Ach-induced vasorelaxation was due to nitric oxide (NO) bioavailability (i.e., proper function of healthy endothelial cells), not due to NO insensitive (i.e., with adequate NO provided by SNP as NO donor, the vessel could be dilated to the full extent).

6. The Methylation Potential and Redox Status in the Liver of the db/db Mice with Elevated Blood Hcy Level

As a powerful catechol-O-methyltransferase inhibitor, SAH specifically dominates the methylation of polyphenols, such as SAA [39, 50]. Therefore, a high expression of SAH and low methylation potential would inhibit Hcy methylation and hence limiting the Hcy-lowering capability via a remethylation pathway. In our study, the SAH level in the DM (methionine + SAA) group was significantly higher than that in the DM (SAA) and non-DM groups, while the SAH level in the DM (methionine) group was also higher than that in the non-DM group, though the difference did not reach a significant level. Besides, the SAM level was high in the DM (methionine + SAA) group when compared to the DM (SAA) and non-DM groups. At the same time, the SAM/SAH ratio or methylation potential was also found reduced in the DM (methionine + SAA) group when compared to the DM (control) group. These observations suggested that the methylation capacity in the db/db mice with elevated Hcy level was lowered after SAA treatment. Since, we also found that the treatment of SAA could effectively lower down the Hcy level in the DM (methionine + SAA) group by nearly half when compared to the DM (methionine) group (Figure 3). Thus, it is likely that the remethylation process of Hcy has been largely inhibited by the elevated SAH level in the DM (methionine + SAA) group and that the observed Hcy-lowering effect by SAA treatment on the db/db mice with elevated Hcy level is most likely through the alternative pathway, that is, the transsulfuration pathway.

Transsulfuration pathway provides an endogenous pathway for the conversion of Hcy into GSH [30, 51]. The significance of the transsulfuration pathway is in the maintenance of the redox homeostasis [52, 53]. In the present study, we found that the GSH level in the DM (SAA + methionine) group was relatively higher when compared to that in the DM (methionine) group after 8 wks of intervention period. This observation further supports our postulation that SAA treatment could normalize Hcy level in the diabetic mice with an elevated Hcy level predominately by activation of transsulfuration pathway and production of more GSH, despite a high expression of SAH and lower methylation potential condition exist after SAA treatment. In addition, the redox imbalance as indicated by reduced GSH/GSSG ratio was significantly elevated in the DM (SAA) group when compared to the DM (control) and non-DM groups, suggesting that SAA is a potent antioxidant. In this study, a higher oxidative stress level was also noted in the db/db mice, as indicated by a lower GSH pool size in the DM (control) group, when compared to the non-DM group. In the setting of diabetes, GSH depletion caused by disturbed transsulfuration could lead to the oxidant/antioxidant imbalance on its own, and the impaired transsulfuration could cause the loss of the compensatory GSH synthesis in response to oxidative stress, and lead to further oxidative stress [51, 52].

7. Conclusion

From our observations, transsulfuration pathway seems to be activated by SAA treatment and is likely served as a potential target for Hcy-lowering and redox-rebalancing treatments in both hyperglycemic and hyperhomocysteinemic diabetic animals. Although other players in the transsulfuration pathway, such as cystathionine and cysteine levels, were not identified in our experiments, the relatively higher GSH levels in the liver of our diabetic mice with elevated Hcy level after SAA treatment already suggested that SAA could activate the activity of the transsulfuration pathway as a means of lowering Hcy level. We believe that SAA is an important endogenous antioxidant and could work as an exogenous antioxidant against ROS-induced harm in the heart and ameliorate endothelial dysfunction. Besides, the elevated GSH level after SAA treatment provides another explanation for the overall improved antioxidant activity of SAA in protecting against the progression of LVH and ED. Further studies into other key players in the transsulfuration pathway, as well as the underlying mechanism/signaling pathway of CV protective effects by SAA treatment in diabetc with HHcy, are warranted.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Christopher W. K. Lai and Parco M. Siu conceived and designed the experiments. Lei Gao performed the experiments. Lei Gao and Christopher W. K. Lai analyzed the data. Lei Gao and Christopher W. K. Lai wrote the paper. Lei Gao, Shun-wan Chan, Christopher W. K. Lai, and Parco M. Siu approved the paper.

Acknowledgments

The authors gratefully acknowledge the financial support from The Hong Kong Polytechnic University (RTKB) and the Griffith University and Hong Kong Polytechnic University Collaborative Research Grants Scheme, as well as the technical support from the Centralized Animal Facilities of The Hong Kong Polytechnic University.

References

[1] L. Guariguata, D. R. Whiting, I. Hambleton, J. Beagley, U. Linnenkamp, and J. E. Shaw, “Global estimates of diabetes prevalence for 2013 and projections for 2035,” Diabetes Research and Clinical Practice, vol. 103, no. 2, pp. 137–149, 2014.
Oxidative Medicine and Cellular Longevity

[2] O. Lorenzo, E. Ramirez, B. Picatoste, J. Egido, and J. Tunon, “Alteration of energy substrates and ROS production in diabetic cardiomyopathy,” *Mediators of Inflammation*, vol. 2013, Article ID 461967, 11 pages, 2013.

[3] J. S. Felicio, C. C. Koury, C. T. Carvalho et al., “Present insights on cardiomyopathy in diabetic patients,” *Current Diabetes Reviews*, vol. 12, no. 4, pp. 384–395, 2016.

[4] D. Jagasia and P. H. McNulty, “Diabetes mellitus and heart failure,” *Congestive Heart Failure*, vol. 9, no. 3, pp. 133–141, 2003.

[5] J. Calles-Escandon and M. Cipolla, “Diabetes and endothelial dysfunction: a clinical perspective,” *Endocrine Reviews*, vol. 22, no. 1, pp. 36–52, 2001.

[6] M. C. Audelin and J. Genest Jr., “Homocysteine and cardiovascular disease in diabetes mellitus,” *Atherosclerosis*, vol. 159, no. 2, pp. 497–511, 2001.

[7] D. J. Wile and C. Toth, “Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy,” *Diabetes Care*, vol. 33, no. 1, pp. 156–161, 2010.

[8] M. Buysschaert, A. S. Dramais, P. E. Wallemacq, and M. P. Hermans, “Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance,” *Diabetes Care*, vol. 23, no. 12, pp. 1816–1822, 2000.

[9] W. A. Bauman, S. Shaw, E. Jayatilleke, A. Spungen, and V. Herbert, “Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin,” *Diabetes Care*, vol. 23, no. 9, pp. 1227–1231, 2000.

[10] M. Sahin, N. B. Tutuncu, D. Ertugrul, N. Tanaci, and N. D. Guvener, “Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus,” *Journal of Diabetes and its Complications*, vol. 21, no. 2, pp. 118–123, 2007.

[11] D. J. Wile and C. Toth, “Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy,” *Diabetes Care*, vol. 33, no. 1, pp. 156–161, 2010.

[12] B. Srećkovic, V. D. Srećkovic, I. Soldatovic et al., “Homocysteine is a marker for metabolic syndrome and atherosclerosis,” *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, vol. 11, no. 3, pp. 179–182, 2017.

[13] J. Heinz, S. Kropf, C. Luley, and J. Dierkes, “Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis,” *American Journal of Kidney Diseases*, vol. 54, no. 3, pp. 478–489, 2009.

[14] T. Huang, J. Ren, J. Huang, and D. Li, “Association of homocysteine with type 2 diabetes: a meta-analysis implementing Mendelian randomization approach,” *BMC Genomics*, vol. 14, no. 1, p. 867, 2013.

[15] M. O. Ebtesumun and E. O. Obahoji, “Elevated plasma homocysteine in type 2 diabetes mellitus: a risk factor for cardiovascular diseases,” *Pan African Medical Journal*, vol. 12, no. 1, 2012.

[16] S. E. Litwin, “Diabetes and the heart: is there objective evidence of a human diabetic cardiomyopathy?,” *Diabetes*, vol. 62, no. 10, pp. 3329–3330, 2013.

[17] J. Kolling, E. B. Scherer, A. A. da Cunha, M. J. da Cunha, and A. T. Wyse, “Homocysteine induces oxidative-nitrative stress in heart of rats: prevention by folic acid,” *Cardiovascular Toxicology*, vol. 11, no. 1, pp. 67–73, 2011.

[18] S. C. Tyagi, W. Rodriguez, A. M. Patel et al., “Hyperhomocysteinemic diabetic cardiomyopathy: oxidative stress, remodeling, and endothelial-myocyte uncoupling,” *Journal of Cardiovascular Pharmacology and Therapeutics*, vol. 10, no. 1, pp. 1–10, 2005.

[19] W. K. Lai and M. Y. Kan, “Homocysteine-induced endothelial dysfunction,” *Annals of Nutrition & Metabolism*, vol. 67, no. 1, pp. 1–12, 2015.

[20] K. C. Tan, O. Karmin, W. S. Chow, V. H. Ai, Y. L. Siow, and K. S. Lam, “Hyperhomocysteinemia and impaired vaso-motor function in type 2 diabetes mellitus,” *European Journal of Clinical Investigation*, vol. 32, no. 5, pp. 328–334, 2002.

[21] A. Koller, M. Balasko, and Z. Bagi, “Endothelial regulation of coronary microcirculation in health and cardiometabolic diseases,” *Internal and Emergency Medicine*, vol. 8, Supplement 1, pp. S51–S54, 2013.

[22] R. Dhananjayan, K. S. Koundinya, T. Malati, and V. K. Kutala, “Endothelial dysfunction in type 2 diabetes mellitus,” *Indian Journal of Clinical Biochemistry*, vol. 31, no. 4, pp. 372–379, 2016.

[23] M. P. McRae, “High-dose folic acid supplementation effects on endothelial function and blood pressure in hypertensive patients: a meta-analysis of randomized controlled clinical trials,” *Journal of Chiropractic Medicine*, vol. 8, no. 1, pp. 15–24, 2009.

[24] A. Valli, J. J. Carrero, A. R. Qureshi et al., “Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients,” *Clinica Chimica Acta*, vol. 395, no. 1, pp. 106–110, 2008.

[25] D. A. Dickinson and H. J. Forman, “Glutathione in defense and signaling,” *Annals of the New York Academy of Sciences*, vol. 973, no. 1, pp. 488–504, 2002.

[26] M. Mari, A. Morales, A. Collell, C. García-Ruiz, and J. C. Fernández-Checa, “Mitochondrial glutathione, a key survival antioxidant,” *Antioxidants & Redox Signaling*, vol. 11, no. 11, pp. 2685–2700, 2009.

[27] S.-G. Cho, Y. H. Lee, H.-S. Park et al., “Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1,” *Journal of Biological Chemistry*, vol. 276, no. 16, pp. 12749–12755, 2001.

[28] R. Franco and J. Cidlowski, “Apopotosis and glutathione: beyond an antioxidant,” *Cell Death & Differentiation*, vol. 16, no. 10, pp. 1303–1314, 2009.

[29] S. Ghosh, T. Pulinilkunnil, G. Yuen et al., “Cardiomyocyte apoptosis induced by short-term diabetes requires mitochondrial GSH depletion,” *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 289, no. 2, pp. H768–H776, 2005.

[30] M. V. Martinov, V. M. Vitvitsky, E. V. Mosharov, R. Banerjee, and F. I. Ataullakhanov, “A substrate switch: a new mode of regulation in the methionine metabolic pathway,” *Journal of Theoretical Biology*, vol. 204, no. 4, pp. 521–532, 2000.

[31] G. Noctor, L. Gomez, H. Vanacker, and C. H. Foyer, “Glutathione in defense,” *Antioxidants & Redox Signaling*, vol. 8, no. 1, pp. 1–17, 2005.

[32] D. P. Jones, J. L. Carlson, V. C. Mody, J. Cai, M. J. Lynn, and P. Sternberg, “Redox state of glutathione in human...
plasma,” *Free Radical Biology and Medicine*, vol. 28, no. 4, pp. 625–635, 2000.

[33] T. O. Cheng, “Danshen: a versatile Chinese herbal drug for the treatment of coronary heart disease,” *International Journal of Cardiology*, vol. 113, no. 3, pp. 437–438, 2006.

[34] H. Li, Y. H. Xie, Q. Yang et al., “Cardioprotective effect of paeonol and danshensu combination on isoproterenol-induced myocardial injury in rats,” *PLoS One*, vol. 7, no. 11, article e48872, 2012.

[35] T. O. Cheng, “Cardiovascular effects of Danshen,” *International Journal of Cardiology*, vol. 121, no. 1, pp. 9–22, 2007.

[36] F. Wang, Y.-Y. Liu, L.-Y. Liu et al., “The attenuation effect of 3,4-dihydroxy-phenyl lactic acid and salvianolic acid B on venular thrombosis induced in rat mesentery by photochemical reaction,” *Clinical Hemorheology and Microcirculation*, vol. 42, no. 1, pp. 7–18, 2009.

[37] J.-Y. Han, Y. Horie, J.-Y. Fan et al., “Potential of 3,4-dihydroxy-phenyl lactic acid for ameliorating ischemia-reperfusion-induced microvascular disturbance in rat mesentery,” *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 296, no. 1, pp. G36–G44, 2009.

[38] K. Chan, S. Chui, D. Wong, W. Ha, C. Chan, and R. Wong, “Protective effects of Danshensu from the aqueous extract of *Salvia miltiorrhiza* (Danshen) against homocysteine-induced endothelial dysfunction,” *Life Sciences*, vol. 75, no. 26, pp. 3175–3171, 2004.

[39] Y. Cao, J. G. Chai, Y. C. Chen et al., “Beneficial effects of danshensu, an active component of *Salvia miltiorrhiza*, on homocysteine metabolism via the trans-sulphuration pathway in rats,” *British Journal of Pharmacology*, vol. 157, no. 3, pp. 482–490, 2009.

[40] P. M. Siu, S. Bae, N. Bodyak, D. L. Rigor, and P. M. Kang, “Response of caspase-independent apoptotic factors to high salt diet-induced heart failure,” *Journal of Molecular and Cellular Cardiology*, vol. 42, no. 3, pp. 678–686, 2007.

[41] S. Gao, D. Ho, D. E. Vatner, and S. F. Vatner, “Echocardiography in mice,” *Current Protocols in Mouse Biology*, vol. 1, pp. 71–83, 2011.

[42] T. D. Nolin, M. E. McMenamin, and J. Himmelfarb, “Simultaneous determination of total homocysteine, cysteine, cysteinylglycine, and glutathione in human plasma by high-performance liquid chromatography: application to studies of oxidative stress,” *Journal of Chromatography B*, vol. 852, no. 1, pp. 554–561, 2007.

[43] K. U. Yun, C. S. Ryu, J.-Y. Lee et al., “Hepatic metabolism of sulfur amino acids in db/db mice,” *Food and Chemical Toxicology*, vol. 53, pp. 180–186, 2013.

[44] Y. Yin, Y. Guan, J. Duan et al., “Cardioprotective effect of Danshensu against myocardial ischemia/reperfusion injury and inhibits apoptosis of H9c2 cardiomyocytes via Akt and ERK1/2 phosphorylation,” *European Journal of Pharmacology*, vol. 699, no. 1, pp. 219–226, 2013.

[45] D. Jay, H. Hitomi, and K. K. Griendling, “Oxidative stress and diabetic cardiovascular complications,” *Free Radical Biology and Medicine*, vol. 40, no. 2, pp. 183–192, 2006.

[46] L. A. Barouch, D. E. Berkowitz, R. W. Harrison, C. P. O’Donnell, and J. M. Hare, “Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice,” *Circulation*, vol. 108, no. 6, pp. 754–759, 2003.

[47] L. Cai, Y. Wang, G. Zhou et al., “Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy,” *Journal of the American College of Cardiology*, vol. 48, no. 8, pp. 1688–1697, 2006.

[48] S. Boudina and E. D. Abel, “Diabetic cardiomyopathy revisited,” *Circulation*, vol. 115, no. 25, pp. 3213–3223, 2007.

[49] P. Yue, T. Arai, M. Terashima et al., “Magnetic resonance imaging of progressive cardiomyopathic changes in the db/db mouse,” *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 292, no. 5, pp. H2106–H2118, 2007.

[50] A. J. Rivett and J. A. Roth, “Kinetic studies on the O-methylolation of dopamine by human brain membrane-bound catechol O-methyltransferase,” *Biochemistry*, vol. 21, no. 8, pp. 1740–1742, 1982.

[51] V. Vitvitsky, E. Mosharov, M. Tritt, F. Ataullakhanov, and R. Banerjee, “Redox regulation of homocysteine-dependent glutathione synthesis,” *Redox Report*, vol. 8, no. 1, pp. 57–63, 2003.

[52] E. Mosharov, M. R. Cranford, and R. Banerjee, “The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes,” *Biochemistry*, vol. 39, no. 42, pp. 13005–13011, 2000.

[53] B. Deplancke and H. R. Gaskins, “Redox control of the transsulfuration and glutathione biosynthesis pathways,” *Current Opinion in Clinical Nutrition & Metabolic Care*, vol. 5, no. 1, pp. 85–92, 2002.